Clinical Trial Update: Emend for Multiple-day Emetogenic Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update on Emend for prevention of nausea and vomiting caused by multiple-day emetogenic chemotherapy; study completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nausea
• Vomiting

Drugs mentioned

• EMEND (aprepitant)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Nausea, Vomiting | Phase 2 | Status: COMPLETED | Results posted: 2009-08-03